Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort.

Stylianos T PanopoulosΚ ChatzidionysiouM G TektonidouV K BourniaA A DrososStamatis-Nick C LiossisT DimitroulasL SakkasD BoumpasP V VoulgariD DaoussisK ThomasG GeorgiopoulosG VosvotekasΑ GaryfallosP SidiropoulosG BertsiasD VassilopoulosP P Sfikakis

Published in: Arthritis research & therapy (2020)

Existing therapeutic limitations indicate that more evidence-based treatment is warranted for successful management of SSc. Vasculopathy seems to be managed more rigorously, but the low retention rates of immunosuppressive/antiproliferative drugs suggest that effective and targeted disease-modifying agents are warranted.

Keyphrases

systemic sclerosis
interstitial lung disease
case report
cancer therapy
combination therapy
drug delivery
adverse drug
free survival